IQVIA Holdings Inc. $IQV Holdings Raised by Equitable Trust Co.

Equitable Trust Co. lifted its stake in IQVIA Holdings Inc. (NYSE:IQV) by 81.5% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 13,140 shares of the medical research company’s stock after purchasing an additional 5,900 shares during the quarter. Equitable Trust Co.’s holdings in IQVIA were worth $2,496,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently bought and sold shares of the company. Brighton Jones LLC raised its holdings in shares of IQVIA by 244.4% during the fourth quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock valued at $703,000 after acquiring an additional 2,537 shares during the period. Empowered Funds LLC grew its position in IQVIA by 102.1% during the 1st quarter. Empowered Funds LLC now owns 9,728 shares of the medical research company’s stock worth $1,715,000 after purchasing an additional 4,915 shares in the last quarter. Sivia Capital Partners LLC acquired a new stake in IQVIA during the 2nd quarter valued at $514,000. Brookstone Capital Management lifted its holdings in shares of IQVIA by 9.2% in the second quarter. Brookstone Capital Management now owns 3,063 shares of the medical research company’s stock valued at $483,000 after purchasing an additional 259 shares in the last quarter. Finally, Asset Management One Co. Ltd. boosted its position in shares of IQVIA by 0.5% in the second quarter. Asset Management One Co. Ltd. now owns 74,107 shares of the medical research company’s stock worth $11,679,000 after buying an additional 395 shares during the period. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Price Performance

NYSE IQV opened at $162.08 on Tuesday. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.09. The stock has a market capitalization of $27.50 billion, a PE ratio of 20.62, a price-to-earnings-growth ratio of 1.60 and a beta of 1.37. IQVIA Holdings Inc. has a 12-month low of $134.65 and a 12-month high of $247.04. The company has a 50 day moving average price of $216.37 and a two-hundred day moving average price of $208.54.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Thursday, February 5th. The medical research company reported $3.42 earnings per share for the quarter, beating analysts’ consensus estimates of $3.40 by $0.02. The business had revenue of $4.36 billion for the quarter, compared to the consensus estimate of $4.24 billion. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. IQVIA’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same quarter last year, the firm earned $3.12 EPS. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. As a group, equities analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on IQV. Citigroup reduced their price objective on IQVIA from $230.00 to $200.00 and set a “neutral” rating for the company in a research note on Friday, February 6th. Mizuho set a $215.00 price target on shares of IQVIA in a research report on Monday. JPMorgan Chase & Co. decreased their price target on shares of IQVIA from $255.00 to $225.00 and set an “overweight” rating for the company in a report on Friday, February 6th. Truist Financial dropped their price objective on shares of IQVIA from $290.00 to $245.00 and set a “buy” rating on the stock in a research note on Thursday. Finally, Robert W. Baird set a $258.00 target price on shares of IQVIA and gave the company an “outperform” rating in a research note on Wednesday, October 29th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $231.80.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.